9D9 antibody is specific for mouse CTLA-4. The antibody has been used to block CTLA-4 and has been shown to enhance T-cell immunity against tumours. 9D9 also has an anti-B16/BL6 melanoma effect in non-irradiated tumour-bearing recipients when given as combinatorial therapy with Gvax. This mechanism both involves blockade of CTLA4 as well as depletion of tumor-infiltrating regulatory T-cells. Fc Silent antibodies were shown to have reduced anti-tumor activity as they did not deplete tumor infiltrating regulatory T-cells, however they lead to expansion of peripheral Tregs.
Specifications
Catalog Number:
KB-1250
Antibody Name:
9D9-mIgG2a
Isotype:
Mouse IgG2a, kappa
FC Muations:
Wild Type
Target:
Mouse CTLA4
Species Reactivity:
Mouse
Host Cell Line:
EXPI CHO
Purification Method:
Affinity purified
Concentration:
>2 mg/mL
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Purity:
>95% by SDS-PAGE and HPLC
Validation:
ELISA | in vivo animal study
Endotoxin Level:
<0.2 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Storage:
It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability:
Stable for twelve months from date of receipt when stored at -20°C to -80°C;Stored at 2-8°C for one month without detectable loss of activity.
Characterization
Application
References
Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancer immunotherapy. Adv. Immunol. 2006;90:297–339. doi: 10.1016/S0065-2776(06)90008-X.
Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271:1734–1736.
